The study of a new medicine (RO7303359) in people with a type of eye disease (geographic atrophy secondary to age-related macular degeneration)

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Eye Disorder
Dry Macular Degeneration
Geographic Atrophy

Results
Download
Print

Study results

LPS GR42163 Final Results December 2023 English (PDF, 0.1 MB)

LPS GR42163 Final Results December 2023 US Spanish (PDF, 0.1 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

The study of a new medicine (RO7303359) in people with a type of eye disease (geographic atrophy secondary to age-related macular degeneration)

Study results

LPS GR42163 Final Results December 2023 English (PDF, 0.1 MB)

LPS GR42163 Final Results December 2023 US Spanish (PDF, 0.1 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

Directly contact Roche for questions

Contact the hospital directly

Thank you

Something went wrong

Request a call back

Find participating medical centers and current study status in each of them

The study of a new medicine (RO7303359) in people with a type of eye disease (geographic atrophy secondary to age-related macular degeneration)

For the latest version of this information please go to www.forpatients.roche.com